Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation and Depletion: 2016-2018

Historic Depreciation and Depletion for Cytokinetics (CYTK) over the last 2 years, with Dec 2018 value amounting to -$359,000.

  • Cytokinetics' Depreciation and Depletion fell 160.85% to -$359,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 million, marking a year-over-year decrease of 36.84%. This contributed to the annual value of $9.5 million for FY2024, which is 20.17% down from last year.
  • According to the latest figures from Q4 2018, Cytokinetics' Depreciation and Depletion is -$359,000, which was down 233.96% from $268,000 recorded in Q3 2018.
  • Cytokinetics' 5-year Depreciation and Depletion high stood at $673,000 for Q1 2018, and its period low was -$359,000 during Q4 2018.
  • For the 3-year period, Cytokinetics' Depreciation and Depletion averaged around $364,778, with its median value being $439,000 (2017).
  • Per our database at Business Quant, Cytokinetics' Depreciation and Depletion spiked by 222.40% in 2017 and then slumped by 160.85% in 2018.
  • Over the past 3 years, Cytokinetics' Depreciation and Depletion (Quarterly) stood at $183,000 in 2016, then surged by 222.40% to $590,000 in 2017, then plummeted by 160.85% to -$359,000 in 2018.
  • Its Depreciation and Depletion stands at -$359,000 for Q4 2018, versus $268,000 for Q3 2018 and $618,000 for Q2 2018.